Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven Fishbane

Showing results (151-160 of 234) with videos related to

Pageof 24
Sort By:
Hemodialysis International. International Symposium on Home Hemodialysis|December 20, 2021
Dose effect analysis of sodium zirconium cyclosilicate in hemodialysis patientsBruce Spinowitz, Kieran McCafferty, Steven Fishbane, et al.
Kidney Medicine|August 30, 2022
Safety and Tolerability of Difelikefalin for the Treatment of Moderate to Severe Pruritus in Hemodialysis Patients: Pooled Analysis From the Phase 3 Clinical Trial ProgramSteven Fishbane, Warren Wen, Catherine Munera, et al.
Clinical Nephrology|August 10, 2012
Factors affecting response and tolerability to ferumoxytol in nondialysis chronic kidney disease patientsSteven Fishbane, W Kline Bolton, Wolfgang C Winkelmayer, et al.
Clinical Therapeutics|July 10, 2007
Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal diseaseAnatole Besarab, Moro O Salifu, N Martin Lunde, et al.
Journal of the American Society of Nephrology : JASN|January 14, 2017
Effects of Ferric Citrate in Patients with Nondialysis-Dependent CKD and Iron Deficiency AnemiaSteven Fishbane, Geoffrey A Block, Lisa Loram, et al.
Clinical Kidney Journal|October 18, 2024
Chronic kidney disease-associated pruritus and quality of life with difelikefalin treatment: a <i>post hoc</i> analysis of phase 3 data using the Skindex-10 questionnaireSonja Ständer, Steven Fishbane, Thilo Schaufler, et al.
Kidney Medicine|August 1, 2020
Continuous Glucose Monitoring and Glycemic Control in Patients With Type 2 Diabetes Mellitus and CKDLubaina Presswala, Susana Hong, Yael Harris, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|July 31, 2021
Hypoxia-Inducible Factor Stabilization as an Emerging Therapy for CKD-Related Anemia: Report From a Scientific Workshop Sponsored by the National Kidney FoundationJay B Wish, Kai-Uwe Eckardt, Csaba P Kovesdy, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 14, 2020
Serum potassium laboratory reference ranges influence provider treatment behaviors for hyperkalemiaJamie S Hirsch, Rushang Parikh, Safiya Richardson, et al.
Haematologica|November 25, 2014
Hypersensitivity reactions to intravenous iron: guidance for risk minimization and managementDavid Rampton, Joergen Folkersen, Steven Fishbane, et al.
Pageof 24

Showing results (151-160 of 234) with videos related to

Sort By:
Pageof 24
Hemodialysis International. International Symposium on Home Hemodialysis|December 20, 2021
Dose effect analysis of sodium zirconium cyclosilicate in hemodialysis patientsBruce Spinowitz, Kieran McCafferty, Steven Fishbane, et al.
Kidney Medicine|August 30, 2022
Safety and Tolerability of Difelikefalin for the Treatment of Moderate to Severe Pruritus in Hemodialysis Patients: Pooled Analysis From the Phase 3 Clinical Trial ProgramSteven Fishbane, Warren Wen, Catherine Munera, et al.
Clinical Nephrology|August 10, 2012
Factors affecting response and tolerability to ferumoxytol in nondialysis chronic kidney disease patientsSteven Fishbane, W Kline Bolton, Wolfgang C Winkelmayer, et al.
Clinical Therapeutics|July 10, 2007
Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal diseaseAnatole Besarab, Moro O Salifu, N Martin Lunde, et al.
Journal of the American Society of Nephrology : JASN|January 14, 2017
Effects of Ferric Citrate in Patients with Nondialysis-Dependent CKD and Iron Deficiency AnemiaSteven Fishbane, Geoffrey A Block, Lisa Loram, et al.
Clinical Kidney Journal|October 18, 2024
Chronic kidney disease-associated pruritus and quality of life with difelikefalin treatment: a <i>post hoc</i> analysis of phase 3 data using the Skindex-10 questionnaireSonja Ständer, Steven Fishbane, Thilo Schaufler, et al.
Kidney Medicine|August 1, 2020
Continuous Glucose Monitoring and Glycemic Control in Patients With Type 2 Diabetes Mellitus and CKDLubaina Presswala, Susana Hong, Yael Harris, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|July 31, 2021
Hypoxia-Inducible Factor Stabilization as an Emerging Therapy for CKD-Related Anemia: Report From a Scientific Workshop Sponsored by the National Kidney FoundationJay B Wish, Kai-Uwe Eckardt, Csaba P Kovesdy, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 14, 2020
Serum potassium laboratory reference ranges influence provider treatment behaviors for hyperkalemiaJamie S Hirsch, Rushang Parikh, Safiya Richardson, et al.
Haematologica|November 25, 2014
Hypersensitivity reactions to intravenous iron: guidance for risk minimization and managementDavid Rampton, Joergen Folkersen, Steven Fishbane, et al.
Pageof 24